Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Merck Gives Back Galapagos Programs
by Lisa M. Jarvis
February 14, 2011
| A version of this story appeared in
Volume 89, Issue 7
Merck & Co. has ended its obesity, diabetes, and atherosclerosis drug discovery collaboration with Galapagos. The Belgian biotech firm will receive $16 million for work completed in 2010, bringing total payments from Merck in the past two years to roughly $28 million. Galapagos regains the rights to all targets discovered and assays developed by the alliance, which began in early 2009 as a metabolic diseases collaboration and was later expanded to include atherosclerosis. Merck says it is ending the pact as a result of changes in its early discovery strategy.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X